AutoICD API

75547-0

Laboratory

Noninvasive prenatal fetal aneuploidy and microdeletion panel based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific circulating cell free (ccf) DNA

Definition

Noninvasive prenatal screening is used to assess fetal risk for various genetic conditions without requiring invasive maternal procedures such as amniocentesis or chorionic villus sampling. Cell-free DNA (cfDNA) in maternal plasma comes from both fetal and maternal sources, and depending on the technology used, this DNA can be used to determine fetal risk for a variety of conditions including aneuploidy (e.g., Trisomy 21, Monosomy X) and microdeletions (e.g., 22q11.2 deletion). This panel was developed for, but is not limited in use to, Natera's Panorama prenatal test, which incorporates SNP analysis of maternal white blood cell DNA with combined maternal and fetal cfDNA SNP analysis. Natera's proprietary informatics analysis method (NATUS) effectively subtracts the maternal genotype from the cfDNA genotype and analyzes the remaining fetal cfDNA genotype for certain aneuploidies and microdeletion syndromes.

LOINC 6-Axis Classification

Component

Noninvasive prenatal fetal aneuploidy and microdeletion panel

Property

-

Time Aspect

Pt

System

WBC.DNA+Plas.cfDNA

Scale Type

-

Method Type

Dosage of chromosome specific cf DNA

Details

Class

PANEL.MOLPATH

Order/Observation

Order

Short Name

NIP aneu microdel pnl WBC.DNA+cfDNA

Display Name

Noninvasive prenatal fetal aneuploidy and microdel panel Dosage of chromosome-specific cfDNA (Plasma cell-free+WBC DNA)

Related Names

ChromosomChromosomesLeukocytesMolecular pathologyMOLPATHNIP fet aneu microdel pnlPanPanel.molpathPanlPlPlasmaPlsmPnlPoint in timeRandomSpecWBC.DNA+cfDNAWBCsWhite blood cells

Frequently Asked Questions

What is LOINC code 75547-0?

LOINC code 75547-0 identifies "Noninvasive prenatal fetal aneuploidy and microdeletion panel based on Plasma cell-free+WBC DNA by Dosage of chromosome-specific circulating cell free (ccf) DNA". Noninvasive prenatal screening is used to assess fetal risk for various genetic conditions without requiring invasive maternal procedures such as amniocentesis or chorionic villus sampling. Cell-free DNA (cfDNA) in maternal plasma comes from both fetal and maternal sources, and depending on the technology used, this DNA can be used to determine fetal risk for a variety of conditions including aneuploidy (e.g., Trisomy 21, Monosomy X) and microdeletions (e.g., 22q11.2 deletion). This panel was developed for, but is not limited in use to, Natera's Panorama prenatal test, which incorporates SNP analysis of maternal white blood cell DNA with combined maternal and fetal cfDNA SNP analysis. Natera's proprietary informatics analysis method (NATUS) effectively subtracts the maternal genotype from the cfDNA genotype and analyzes the remaining fetal cfDNA genotype for certain aneuploidies and microdeletion syndromes.

What does 75547-0 measure?

This code measures Noninvasive prenatal fetal aneuploidy and microdeletion panel in WBC.DNA+Plas.cfDNA. It belongs to the PANEL.MOLPATH class in the LOINC classification.

What is LOINC?

LOINC (Logical Observation Identifiers Names and Codes) is a universal standard for identifying laboratory and clinical observations. It is maintained by the Regenstrief Institute and used worldwide for health data exchange.